Catalyst Brief

← Calendar

Readoutin 135d

RHEACELL GmbH & Co. KG — allo-APZ2-CVU

Phase 3 primary completion: Allogeneic ABCB5-positive Dermal Mesenchymal Stromal Cells for Treatment of Therapy-resistant CVU (Phase III).

Date
Apr 2027
Type
Readout
Indication
Venous Leg Ulcer

Source ↗Add to calendar

Get told when this date moves

The weekly brief is free. Pro adds reminders 7 days and 1 day before.